Containment Genetic Engineering Immune Response Manufacturing 
pharmaphorum
AUGUST 23, 2021
Ahmedabad-based Zydus Cadila has said it expects to launch ZyCoV-D in late September or early October, and expects to be able to manufacture around 100-120 million doses a year, with around 10 million available at launch. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.
The Pharma Data
DECEMBER 16, 2020
Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. About Novavax.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
NOVEMBER 23, 2020
Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. As a manufacturing partner for Oxford’s vaccine, AstraZeneca is ramping up its production capabilities as it plans to make up to three billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval.
The Pharma Data
NOVEMBER 30, 2020
We continue to make meaningful progress as we work to test, manufacture and ultimately deliver NVX-CoV2373 with unprecedented speed, as well as put partnerships in place that would ensure widespread and equitable access worldwide.”. and Mexico pivotal Phase 3 trial and manufacturing scale-up. . Mexico pivotal Phase 3 trial update.
XTalks
AUGUST 17, 2020
Treatment vaccines : these boost the immune system responses to target cells. Immune system modulators (i.e. receptors) of the immune system to enhance, or suppress immune responses. protein-based biologics) : are those which bind to specific components (i.e. Nature by Design. Image from Cue Biopharma.
The Pharma Data
SEPTEMBER 8, 2020
Continue to adhere to high scientific and ethical standards regarding the conduct of clinical trials and the rigor of manufacturing processes. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.
The Pharma Data
SEPTEMBER 8, 2020
Continue to adhere to high scientific and ethical standards regarding the conduct of clinical trials and the rigor of manufacturing processes. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech. This press release contains “forward-looking statements” of. Every day, Pfizer.
Expert insights. Personalized for you.
98 
Let's personalize your content